ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, clinical research center, investigator site, patient recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety and risk-based monitoring, clinical data management, strategic analysis and data operation, regulatory consulting, and medical reporting and pharmacovigilance services. Its clinical development services also comprise interactive response technologies, electronic endpoint adjudication, medical imaging, adaptive trial design and execution, medical device and biosimilar trial, functional, strategic resourcing, sample analyses, safety testing, microbiology, custom flow cytometry, biomarker development, bioanalysis, immunoassay development, patient registries, outcomes research, health economics, market access and commercialization, drug price consulting, and healthcare and scientific communication services, as well as research trials for the U.S. government agencies, electronic transmission of test results, and electronic patient reported outcomes. The company was founded in 1990 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ICLR
Previous Symbol
CUSIPN/A
Phone353-1291-2000
Debt
Debt-to-Equity Ratio0.26
Current Ratio2.17
Quick Ratio2.17
Price-To-Earnings
Trailing P/E Ratio23.80
Forward P/E Ratio21.10
P/E Growth1.91
Sales & Book Value
Annual Sales$1.76 billion
Price / Sales3.94
Cash Flow$6.3721 per share
Price / Cash20.13
Book Value$22.02 per share
Price / Book5.83
Profitability
EPS (Most Recent Fiscal Year)$5.39
Net Income$281.48 million
Net Margins12.88%
Return on Equity26.08%
Return on Assets14.62%
Miscellaneous
Employees13,250
Outstanding Shares54,080,000
Market Cap$7.19 billion
OptionableOptionable
